Ravulizumab

Chemical Properties

CAS No.	1803171-55-2	Cat. No.	BCP46121
Name	Ravulizumab
Synonyms	ALXN-1210;ALXN1210;
Formula		M. Wt

Biological Activity

Description	Ravulizumab, a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, is being evaluated as a treatment for COVID-19-related severe pneumonia, acute lung injury, and acute respiratory distress syndrome in an ongoing phase 3 randomized controlled trial (ALXN1210-COV-305).

Description

Ravulizumab, a humanized monoclonal antibody that binds with high affinity to complement protein C5 and inhibits terminal complement activation, is being evaluated as a treatment for COVID-19-related severe pneumonia, acute lung injury, and acute respiratory distress syndrome in an ongoing phase 3 randomized controlled trial (ALXN1210-COV-305).

Structure

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Service & Tech Support:orders@biochempartner.com

Website:www.biochempartner.com

Products are for research use only and not for human use. We do not sell to patients.